PharmaMar enters into a distribution license agreement with Megapharm for the commercialisation of anticancer drug Aplidin (plitidepsin) in Israel derived from marine.
As per the terms stated in the agreement, Megapharm possesses the authority to register Aplidin on behalf of PharmaMar to distribute the compound in both the regions. However, PharmaMar still possesses the exclusive production rights to supply the finished products meant for commercial and clinical use. The company stated in 2016 that plitidepsin responded positively in a phase III clinical trial for multiple myeloma. Therefore the second most advanced anticancer drug is under development for curing multiole myeloma and angioimmunoblastic T-cell lymphoma.
Miron Drucker, CEO of Megapharm, stated that, “the agreement between PharmaMar and Megapharm offers a major advance for healthcare in our territory as Aplidin provides a novel mechanism of action for treating multiple myeloma; we hope to bring access to the most innovative treatments to our patients in Israel and the territory known as the Palestinian Authority.”